SiliconInvestor
     Advanced Search   [ sign in ]

register
Register

 Biotech / Medical : Biotech Valuation

 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  
To: Biomaven who wrote (32626)10/16/2009 12:01:54 AM
From: hmpaRead Replies (1) of 40274
 
However, the high inter- and intraindividual variability in sCT exposure demonstrates the importance of determining the optimum conditions for ensuring the most beneficial sCT uptake.

I guess, Novartis and Nordic Biosciences figured some way to resolve the variability issue before starting three Ph 3 trials for SMC021 with about 3K total participants (1st should be completed in 2010, the other two in 2011).
Report TOU ViolationShare This Post
 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQ
Copyright © 1995-2013 Knight Sac Media. All rights reserved.